Search Results
790 results
Your search is now limited to «Company Strategy» expert search.
WN.com 03/25/2019 07:48
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company’s (NYSE:BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG). In addition to its March 19 investor presentation, the Company today also made available on Bristol-Myers Squibb’s website at www.bestofbiopharma.com and later today will file with the Securities and Exchange Commission (SEC) an investor presentation p ......
More from WN.com:
GlobeNewswire 03/25/2019 07:30
GAITHERSBURG, Md., March 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, at the VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship , held March 27-29 at the Intercontinental Hotel in Santiago de Cali, Colombia. Both companies are sponsors of the conference and will have an exhibit.
More from GlobeNewswire:
The registration statement was declared effective by the SEC on February 22, 2019, and Bristol-Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019.
More from Global Banking & Finance Review:
Seeking Alpha 03/25/2019 06:34
Back in early January, Bristol-Myers Squibb Co. (BMY) made an offer to acquire Celgene Corp. (CELG.
More from Seeking Alpha:
FiercePharmaManufacturing 03/22/2019 11:13
Currently, Biogen’s Spinraza leads the market and costs $750,000 before discounts for the first year, then $375,000 before discounts for subsequent years.
More from FiercePharmaManufacturing:
CNBC - Business 03/22/2019 08:57
Biogen stock fall shows drug investment model is wrong: Ex-Aetna CEO.
More from CNBC - Business:
ENDPOINTS 03/22/2019 06:21
A day after Biogen rattled the biopharma world with the news that its lead late-stage therapy aducanumab proved worthless in treating Alzheimer’s — a disaster that may drive a stake through the heart of the amyloid beta theory once and for all — the big biotech’s partners at Eisai have come up with their next big move ...
More from ENDPOINTS:
GaBI Online 03/22/2019 06:03
As part of the transaction, Biogen will enter into manufacturing services agreements with Fujifilm, under which Fujifilm will use the Hillerød site to produce commercial products for Biogen, such as Tysabri, as well as other third-party products.
More from GaBI Online:
During the launch event, Merck Foundation awarded Her Excellency to acknowledge her efforts as 'Merck More Than a Mother' Ambassador in the country.
More from Middle East North Africa Financial Network (MENAFN):
PharmTech.com 03/21/2019 16:00
Merck KGaA also announced that the company management and the Joint Works Council have signed a comprehensive agreement to secure the future viability of company headquarters as a central science and technology hub and to further expand ...
More from PharmTech.com:
Becker's Hospital Review 03/21/2019 13:55
Johnson & Johnson will test the Apple Watch's ability to perform early detection and diagnosis of atrial fibrillation, a type of irregular heartbeat that can signal a stroke.
More from Becker's Hospital Review:
BioPharma Dive 03/21/2019 11:50
Darmstadt is roughly 20 miles south of Frankfurt and home to multiple science-based organizations beyond Merck, including the European Space Agency's main mission control and an intergovernmental organization focused on operating meteorological satellites.
More from BioPharma Dive:
World Pharma News 03/21/2019 07:00
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics.
More from World Pharma News:
Reuters.com 03/20/2019 11:07
REUTERS/Arnd Wiegmann (Reuters) - Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company’s experimental gene therapy for a rare genetic ...
More from Reuters.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications